Certara (CERT) announced the launch of Certara IQ, an AI-powered platform designed to speed up and simplify Quantitative Systems Pharmacology modeling. This approach plays a growing role in drug discovery and regulatory submissions.

Certara’s latest product launch comes on the heels of a notable rebound in its share price. After a setback earlier in the month, shares have rallied for a 21.9% gain over the past 90 days. That renewed momentum stands out against a solid 13.5% total shareholder return for the year, hinting that investor confidence is growing as the company delivers fresh innovation.

If Certara’s progress has you thinking about what’s next in healthcare technology, it’s a great time to explore the landscape with our See the full list for free.

With the launch of Certara IQ and shares still trading at a notable discount to analyst targets, investors face an important question: is Certara undervalued after its latest run, or are expectations for future growth already priced in?

Most Popular Narrative: 21.2% Undervalued

Certara's most widely followed narrative sees fair value at $14.75, well above the latest close of $11.63. This creates an opportunity for further discussion on the stock's potential if management achieves its objectives.

The upcoming commercial launch of Certara's next-generation, AI-enabled MIDD platform and CertaraIQ QSP software leverages advanced analytics and machine learning, providing differentiated capabilities that open access to a broader customer base. This is expected to result in higher recurring revenue and margin expansion through cloud-based SaaS models.

Want to know what’s fueling analysts’ bullish price? The narrative is built on bold assumptions about scalable software, margin expansion, and record new revenues. Discover which financial levers they’re pulling for this forecast and why the numbers could surprise you.

Result: Fair Value of $14.75 (UNDERVALUED)

However, execution risk and the unpredictability of pharma R&D budgets could quickly undermine Certara’s growth story if sector momentum slows.

Build Your Own Certara Narrative

If the prevailing narrative doesn’t match your perspective, you can dig into the numbers and craft your own view in just a few minutes. Do it your way

A great starting point for your Certara research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Smart investors know the best opportunities are just a step away. If you want to stay ahead, don’t overlook these dynamic stock ideas you can act on now:

• Tap into high-yield potential by checking out these 22 dividend stocks with yields > 3%, which offers strong track records and steady income streams for investors focused on regular returns.
• Stay on the leading edge of artificial intelligence by reviewing these 26 AI penny stocks, which promise game-changing innovation and forward-looking growth prospects in tech.
• Capitalize on value plays and strengthen your portfolio by considering these 832 undervalued stocks based on cash flows, which may be poised for their next significant move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.